Dr Lopes speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from a trial that show front line pembrolizumab surpassed chemotherapy for lung cancer patients whose tumours had PD-L1 expression and no EGFR/ALK rearrangements.

For more on these results, watch Dr Lopes present the data in a press conference here and read news coverage here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.